Epoprostenolilla

Epoprostenolilla is a synthetic analogue of prostacyclin, a naturally occurring lipid that plays a crucial role in vasodilation and inhibiting platelet aggregation. It is primarily used in the treatment of pulmonary arterial hypertension (PAH), a severe condition characterized by high blood pressure in the arteries of the lungs. Epoprostenolilla works by relaxing and widening the blood vessels in the lungs, which reduces the pressure and improves blood flow, thereby easing the symptoms of PAH.

The administration of epoprostenolilla is typically done through continuous intravenous infusion, requiring a special pump and central venous catheter. Due to its short half-life, it needs to be administered continuously to maintain therapeutic levels. The dosage is carefully titrated by healthcare professionals based on the patient's response and tolerance. Common side effects can include flushing, nausea, vomiting, headache, and jaw pain, often related to vasodilation.

Beyond PAH, epoprostenolilla may also be used in certain cases of pulmonary hypertension associated with congenital heart disease or other specific conditions. Its use is generally reserved for patients with severe PAH or those who have not responded adequately to other treatments. The management of epoprostenolilla therapy requires close medical supervision and patient education due to the complexities of administration and potential side effects.